Citizens Downgrades Foghorn Therapeutics (FHTX) to Market Perform Oct 1, 2026 02:55PM
Citizens Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX) Ahead of Ph1 Results Sep 17, 2026 04:10AM
Citizens Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX) Mar 17, 2026 05:27AM
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences Aug 27, 2025 07:00AM
Citizens JMP Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX) May 15, 2025 04:11AM


Apr 30, 2025 04:49AM Citizens JMP Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX)
Apr 23, 2025 02:53AM Citizens JMP Starts Foghorn Therapeutics (FHTX) at Market Outperform
Nov 12, 2024 07:54AM Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Apr 16, 2024 07:01AM Foghorn Therapeutics (FHTX) Announces Appointment of Kristian Humer as Chief Financial Officer
Apr 16, 2024 07:00AM Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Apr 24, 2023 08:23AM Coca-Cola, Credit Suisse and Philips rise premarket; Bed Bath&Beyond falls